Start the conversation
When I recommended TrovaGene Inc. (Nasdaq: TROV) back in March, I described it as the single-best profit idea I'd seen in months.
And the stock didn't let me down.
Shares of the San Diego-based "liquid-biopsy" company doubled in just three months after we recommended them back on March 11.
When the stock sold off after that skyrocket rally, we told you all not to worry. In fact, we advised you to turn that weakness into an opportunity - and accumulate more shares.
This is premium content for Private Briefing subscribers only.